4,901 trials
Pain
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Last Observed Concentration at Time t (AUC[0-t]) for Ibuprofen in Fasted Conditions — 122.2406; 122.1489…
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin — 9.45; 23.0; 23.0 nanograms per milliliter (ng/mL)
Myelodysplastic Syndromes · Leukemia, Myelomonocytic, Chronic · Leukemia, Myeloid, Acute
Primary: Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for Pevonedistat Following a Single Dose — 1168.616; 1293.467; 1050.553…
HIV
Primary: Assessement of Safety — 0; 0 Participants
Bladder Cancer
Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants
Diabetes Mellitus, Type 1
Primary: Pharmacodynamics (PD): Change in Plasma Glucose (PG) From the Start to the End of Exercise — -26.8; -46.9; -39.0; -60.5 milligram per Deciliter (mg/dL) — p=0.0494
Healthy
Primary: Maximum Observed Concentration (Cmax) of UPB-101 — 11.6; 24.4; 35.1; 34.9 ug/mL
Healthy
Primary: Slope of the Placebo-corrected Change From Baseline of Heart Rate at Rest and Plasma Concentration Between 0 to 10 Hours — 0.80; 5.46 beats/min
Stage 0a Bladder Cancer AJCC v8 · Stage 0is Bladder Cancer AJCC v8 · Stage I Bladder Cancer AJCC v8
Primary: Urinary Isothiocyanates Levels — 10.4; 4.3 mM — p=0.28
All Malignancies · Advanced Malignancies · Hematologic Malignancy
Primary: Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hours of Quantifiable Concentration (AUC0-12h) of Tazemetostat — 2180; 1830…
Pain
Primary: Maximum Observed Plasma Concentration (Cmax) for Ibuprofen — 36879.50; 38875.03 nanogram per milliliter (ng/mL)
Asthma
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 3; 2; 2; 3 Participants
Autoimmune Diseases
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 0; 0; 0 participants
Psoriasis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs) — 3; 9; 7; 11 Participants
Sleep Disturbance
Primary: Mean System Usability Score (SUS) — 76.27 score on a scale